BioSyent Inc (RX.V)

Would rate this as a Buy, but not a strong Buy. He is comfortable that they can grow their profits over the next 3 years by 25%-30% per year. However, this company is narrowly focused on 1 or 2 products, and they need to diversify beyond that. He thinks they will get there. A good name to own at the $7.50-$8 level.

(A Top Pick June 4/14. Up 15.41%.) This is smallish and conservative, but continues to improve its numbers. Continues to get its products, mostly iron related, into pharmacies all across Canada. He is confident they can continue to increase their product range.

The issue with this is that it is too dependent on a single product. When people started realizing how much of their earnings came from one product, it made him nervous. As it overshot up into that $11-$12 range, it got really extended. It has now checked back and he would rate it is a Buy again. He is pretty comfortable that over the next 2-3 years it will grow its top line and its bottom line at 30% per annum for the next 3 years. They now have a whole bunch of other new products that they have already launched and are starting to ramp up.

Very steady, careful accumulator of products to market in Canada in the medical field.

Likes the story but the valuation is a bit too high. It is not that liquid of a stock. Hard to buy in a fund, but okay for individual investors. Prefers MLS-T.

A small pharmaceutical company. What he likes is that it looks more like Paladin Labs more than anything in the market. Not cheap. P/E ratio is in the high 20s, but the ROE is almost 50%, so he thinks the growth rate is justified. Try to buy this below $10.

This is one that you should just stay with. Because of the condition of the market, you don’t expect anything to be rip roaring upwards unless it has special news. This is a very, very nice company. Steady, reliable.

Chart has a strong upward trend this year and it looks like it is going to go higher. Doesn't see any problems.

Have the rights to very solid, very reliable products. It is just now being discovered and is making new highs.

Very solid small company that has a series of products that are established, seasoned, global products, and it gets the Canadian marketing rates. A few of their people have a big history out there in the big pharma companies, and they want to do their own thing.

Very, very good management team. Some really good products. Has a lot of cash. Very high ROE. He owns it, but doesn’t have a massive position in it because it is quite a small company. A good, long-term growth story. Symptomatic of the issues of a lot of the great growth companies, i.e., they were trading in the single digit PE ratios but are now trading in the high teens or mid-20s. Not cheap, but a great one.